header image

News

Octapharma donates Nuwiq® to the WFH Humanitarian Aid Program to provide patients with haemophilia A in developing countries access to therapy

22.12.2016

Lachen, Switzerland, December 22nd, 2016: Octapharma is proud to announce that the company has made a charitable donation of 4.5 million units of its fourth generation, human cell-line derived recombinant factor VIII product,...

Octapharma presents key data with Nuwiq® in previously untreated patients from the NuProtect study at the American Society of Hematology (ASH) Annual Meeting in San Diego, USA

21.12.2016

Lachen, Switzerland, December 21st, 2016 – On Sunday, December 4th, 2016 Octapharma presented interim data from the ongoing phase 3 study, NuProtect at the 58th ASH Annual Meeting & Exposition in San Diego, California. The...

Octapharma suspends Mr Paulo Castro from the company

14.12.2016

Lachen, Switzerland, December 14th, 2016: In the context of judicial assistance provided by Switzerland to the authorities in Portugal today, a board member of Octapharma, Mr Paulo Castro, has been subject to inquiries for...

Octapharma Plasma, Inc.’s Testing Laboratory Receives FDA Approval

29.08.2016

Charlotte, N.C., USA, August 25th, 2016: Octapharma Plasma, Inc. receives approval from the U.S. Food and Drug Administration (FDA) for its new state-of-the-art testing laboratory. FDA regulatory approval will enhance...

Octapharma to sponsor two symposia at the 2016 World Federation of Hemophilia (WFH) World Congress in Orlando, USA

22.07.2016

Lachen, Switzerland, July 22nd, 2016: Octapharma will sponsor a range of activities at this year’s WFH World Congress in Orlando, USA, including two symposia and a number of posters and scientific presentations highlighting...

Octapharma Group publishes 2015 annual results reporting revenue of €1.5 billion and operating income of €351 million

08.03.2016

Lachen, Switzerland, March 8th, 2016: the Octapharma Group publishes its 2015 annual results reporting revenue of 1.513 billion Euro, representing an increase of 233 million Euro or 18.2% compared with the 2014 figure. Gross...

Octapharma Australia provides octaplasLG® for free to a young patient with C1q deficiency

20.01.2016

Lachen, Switzerland, January 20th, 2016: Since 2011, Octapharma Australia has provided octaplasLG® (solvent/detergent treated human plasma) without cost to a young patient with C1q deficiency. OctaplasLG® is a...

Page 1 Page 2 next